<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621967</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000152</org_study_id>
    <nct_id>NCT05621967</nct_id>
  </id_info>
  <brief_title>Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation</brief_title>
  <official_title>Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate Phonation therapy to improve symptoms and lung physiology in patients referred&#xD;
      for pulmonary rehabilitation. The study design will be a randomized controlled trial. The&#xD;
      primary outcome is improvement in patient symptoms (Borg dyspnea score). Secondary outcomes&#xD;
      are improvement in time of breath hold, forced vital capacity (FVC), forced expiratory volume&#xD;
      in 1 second (FEV1), negative inspiratory force (NIF) and improvement in quality of life. The&#xD;
      investigators will be investigating tonation breathing techniques (TBT) exercises and&#xD;
      music-driven vocal exercises (MDVE). The study population would be patients who are referred&#xD;
      to pulmonary rehabilitation (PR) for symptomatic chronic lung disease. The calculated sample&#xD;
      size for the study would be 16 patients and the duration of the study would be 8 weeks. The&#xD;
      study would be performed after the participant's pulmonary rehabilitation session.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are referred for pulmonary rehabilitation for chronic lung disease and/or&#xD;
      post-COVID19 therapy, and who have had pulmonary function testing already will be approached.&#xD;
      Pulmonary rehabilitation is an 8-week program (meeting 3 times per week for the 8 weeks).&#xD;
      Pulmonary rehabilitation (PR) is the standard of care for patients with chronic lung diseases&#xD;
      and or post-COVID-19 therapy. Eligible study participants will be called prior to their&#xD;
      introductory PR session to explain the research project, and those who are interested will be&#xD;
      given full information and offered time to ask questions. The investigators find this&#xD;
      necessary for logistics, given many of the PR patients rely on scheduled transportation&#xD;
      to/from PR and this will allow those who are interested in obtaining more information and to&#xD;
      consent to the study to arrange for appropriate transportation. Informed consent will be done&#xD;
      in person on an individual basis at their introductory PR session, with 1:1 discussion with&#xD;
      the study staff and the patient.&#xD;
&#xD;
      As this is a pilot study to determine feasibility, and preliminary data (as no data are&#xD;
      currently available for this patient population), the investigators propose 16 participants&#xD;
      in total, 4 in each arm of the study. Randomization will occur by random number generator&#xD;
      (1-4 for each arm proposed).&#xD;
&#xD;
      Once informed consent is obtained, patients will be randomized to 4 arms of the study.&#xD;
      Randomization will be performed using a random number generator.&#xD;
&#xD;
        1. Comparing tonation breathing technique (TBT) to normal breathing:&#xD;
&#xD;
             1. Of the 8 weeks of PR, first 4 weeks will be sessions of normal breathing exercises&#xD;
                for 20 minutes, then subsequent 4 weeks will be with TBT intervention for 20&#xD;
                minutes.&#xD;
&#xD;
             2. Of the 8 weeks of PR, the first 4 weeks will be with TBT intervention for 20&#xD;
                minutes, then the next 4 weeks will be of sessions of normal breathing exercises&#xD;
                for 20 minutes.&#xD;
&#xD;
        2. Comparing MDVE to normal breathing:&#xD;
&#xD;
             1. Of the 8 weeks of PR, the first 4 weeks will be sessions of normal breathing&#xD;
                exercises for 20 minutes, then the subsequent 4 weeks will be with Music Driven&#xD;
                Vocal Exercises (MDVE) intervention for 20 minutes.&#xD;
&#xD;
             2. Of the 8 weeks of PR, the first 4 weeks will be with MDVE intervention for 20&#xD;
                minutes, then the next 4 weeks will be of sessions of normal breathing exercises&#xD;
                for 20 minutes.&#xD;
&#xD;
      These interventions would be performed after the usual PR time when patients would be&#xD;
      normally discharged home. Therefore, no additional monitoring is expected.&#xD;
&#xD;
      Pulmonary function testing is standard for all patients who receive PR - testing before and&#xD;
      after PR is routine clinical course. The investigators propose an additional pulmonary&#xD;
      function test (PFT) study at 4 weeks, as part of the research protocol (covered by the&#xD;
      Department of Medicine funding)&#xD;
&#xD;
      In summary, the interventions for research purposes will include:&#xD;
&#xD;
        1. 20-minute sessions after PR for intervention (TBT or MDVE) or normal breathing for twice&#xD;
           a week for the 8 weeks they are participating in PR.&#xD;
&#xD;
        2. PFT at end of week 4&#xD;
&#xD;
      Proposed subjective outcomes are routinely asked of PR patients, but will be collected at&#xD;
      baseline, at 4 weeks (mid-way), and at 8 weeks (end) of PR. Proposed objective outcomes:&#xD;
&#xD;
        1. For FEV1, FVC - these are routinely collected at baseline and at end of PR. The&#xD;
           investigators propose an additional PFT study at 4 weeks, covered by the DOM Faculty&#xD;
           Development Fund.&#xD;
&#xD;
        2. For peak flow and NIF - these are procedures that ask for patients to breathe maximally&#xD;
           for inspiration and expiration. They are not routine measures collected but are routine&#xD;
           bedside measurements for pulmonary patients that can be collected for any person without&#xD;
           any additional risk or cost.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control trial. Randomization for each subject occurs twice. First: One of two types of intervention. Second: Sequence for intervention and normal breathing sessions.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Borg dyspnea score</measure>
    <time_frame>8 weeks</time_frame>
    <description>subjective score of dyspnea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>forced expiratory volume in 1 second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg dyspnea score</measure>
    <time_frame>4 weeks</time_frame>
    <description>subjective score of dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath hold</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>time in seconds participant can hold breath</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QOL)</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>questionnaire on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forced vital capacity (FVC)</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak flow</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>peak flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>negative inspiratory force (NIF)</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>negative inspiratory force</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Silent Breathing / Tonation Breathing Techniques (TBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice a week during the patient's 8 weeks of pulmonary rehabilitation:&#xD;
For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.&#xD;
Next 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silent Breathing / Music Driven Vocal Exercises (MDVE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice a week during the patient's 8 weeks of pulmonary rehabilitation:&#xD;
For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.&#xD;
Next 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tonation Breathing Techniques (TBT) / Silent Breathing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice a week during the patient's 8 weeks of pulmonary rehabilitation:&#xD;
For first 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually&#xD;
Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Music Driven Vocal Exercises (MDVE) / Silent Breathing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice a week during the patient's 8 weeks of pulmonary rehabilitation:&#xD;
For first 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person&#xD;
Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Tonation Breathing Techniques</intervention_name>
    <description>Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.</description>
    <arm_group_label>Silent Breathing / Tonation Breathing Techniques (TBT)</arm_group_label>
    <arm_group_label>Tonation Breathing Techniques (TBT) / Silent Breathing</arm_group_label>
    <other_name>TBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Music Driven Vocal Exercises</intervention_name>
    <description>Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,</description>
    <arm_group_label>Music Driven Vocal Exercises (MDVE) / Silent Breathing</arm_group_label>
    <arm_group_label>Silent Breathing / Music Driven Vocal Exercises (MDVE)</arm_group_label>
    <other_name>MDVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Silent Breathing</intervention_name>
    <description>Patient will sit in a quiet room and focus on silent breathing x 20 min.</description>
    <arm_group_label>Music Driven Vocal Exercises (MDVE) / Silent Breathing</arm_group_label>
    <arm_group_label>Silent Breathing / Music Driven Vocal Exercises (MDVE)</arm_group_label>
    <arm_group_label>Silent Breathing / Tonation Breathing Techniques (TBT)</arm_group_label>
    <arm_group_label>Tonation Breathing Techniques (TBT) / Silent Breathing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  English-speaking and reading patient&#xD;
&#xD;
          -  Able to consent for study&#xD;
&#xD;
          -  Referred for pulmonary rehabilitation for chronic lung disease (including long COVID19&#xD;
             syndrome, COPD, ILD, PH)&#xD;
&#xD;
          -  Baseline Borg dyspnea score as moderate (score 3) or higher.&#xD;
&#xD;
          -  Has baseline pulmonary function testing available in electronic medical record.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Cannot commit to staying an extra 30 min after Pulmonary Rehabilitation sessions for the&#xD;
        study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vidya Krishnan, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University, MetroHealth Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vidya Krishnan, MD, MHS</last_name>
    <phone>216-778-4527</phone>
    <email>vkrishnan@metrohealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Verghese, MD</last_name>
    <phone>330-604-8499</phone>
    <email>everghese@metrohealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidya Krishnan, MD MHS</last_name>
      <phone>216-778-3441</phone>
      <email>vkrishnan@metrohealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Verghese, MD</last_name>
      <phone>330-604-8499</phone>
      <email>everghese@metrohealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ostermann T, Schmid W. Music therapy in the treatment of multiple sclerosis: a comprehensive literature review. Expert Rev Neurother. 2006 Apr;6(4):469-77. doi: 10.1586/14737175.6.4.469.</citation>
    <PMID>16623646</PMID>
  </reference>
  <reference>
    <citation>Garcia-Casares N, Martin-Colom JE, Garcia-Arnes JA. Music Therapy in Parkinson's Disease. J Am Med Dir Assoc. 2018 Dec;19(12):1054-1062. doi: 10.1016/j.jamda.2018.09.025.</citation>
    <PMID>30471799</PMID>
  </reference>
  <reference>
    <citation>Canga B, Azoulay R, Raskin J, Loewy J. AIR: Advances in Respiration - Music therapy in the treatment of chronic pulmonary disease. Respir Med. 2015 Dec;109(12):1532-9. doi: 10.1016/j.rmed.2015.10.001. Epub 2015 Oct 19.</citation>
    <PMID>26522499</PMID>
  </reference>
  <reference>
    <citation>Mathis DR. Melodic sculpturing: the art and science of singing. Bloomington, IN: AuthorHouse, 2009</citation>
  </reference>
  <reference>
    <citation>Price, Kate. The effects of vocal function exercises on the lung function of trained female singers: a pilot investigation. Diss. Victoria University, 2003.</citation>
  </reference>
  <reference>
    <citation>McNamara RJ, Epsley C, Coren E, McKeough ZJ. Singing for adults with chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD012296. doi: 10.1002/14651858.CD012296.pub2.</citation>
    <PMID>29253921</PMID>
  </reference>
  <reference>
    <citation>DRAPER MH, LADEFOGED P, WHITTERIDGE D. Respiratory muscles in speech. J Speech Hear Res. 1959 Mar;2(1):16-27. doi: 10.1044/jshr.0201.16. No abstract available.</citation>
    <PMID>13655288</PMID>
  </reference>
  <reference>
    <citation>Bouhuys A, Proctor DF, Mead J. Kinetic aspects of singing. J Appl Physiol. 1966 Mar;21(2):483-96. doi: 10.1152/jappl.1966.21.2.483. No abstract available.</citation>
    <PMID>5934452</PMID>
  </reference>
  <reference>
    <citation>Leanderson, R.; Sundberg, J. (1988). Breathing for singing. , 2(1), 2-12. doi:10.1016/S0892-1997(88)80051-1</citation>
  </reference>
  <reference>
    <citation>Leanderson R, Sundberg J, von Euler C. Role of diaphragmatic activity during singing: a study of transdiaphragmatic pressures. J Appl Physiol (1985). 1987 Jan;62(1):259-70. doi: 10.1152/jappl.1987.62.1.259.</citation>
    <PMID>3558185</PMID>
  </reference>
  <reference>
    <citation>Huang J, Yuan X, Zhang N, Qiu H, Chen X. Music Therapy in Adults With COPD. Respir Care. 2021 Mar;66(3):501-509. doi: 10.4187/respcare.07489. Epub 2020 Nov 3.</citation>
    <PMID>33144384</PMID>
  </reference>
  <reference>
    <citation>Sliwka A, Nowobilski R, Polczyk R, Nizankowska-Mogilnicka E, Szczeklik A. Mild asthmatics benefit from music therapy. J Asthma. 2012 May;49(4):401-8. doi: 10.3109/02770903.2012.663031. Epub 2012 Mar 7.</citation>
    <PMID>22397390</PMID>
  </reference>
  <reference>
    <citation>Morrison, Ian, and S. M. Clift.</citation>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>September 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>March 13, 2023</last_update_submitted>
  <last_update_submitted_qc>March 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Vidya Krishnan</investigator_full_name>
    <investigator_title>Professor of Medicine: Pulmonary, Critical Care and Sleep Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT05621967/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

